You are here: Industry Insights > Regeneron

News List

FDA approves Regeneron, Sanofi's Dupixent for asthma treatment biospectrum
October 23, 2018
Regeneron and Sanofi recognize that DUPIXENT can only help those uncontrolled moderate-to-severe AD patients that were prescribed the medicine if they can both access the medicine and use it properly.
Sanofi, Regeneron’s Dupixent shines in rhinosinusitis with nasal polyps trials October 19, 2018
Sanofi and Regeneron have unveiled top-line data showing that two late-stage studies of Dupixent in adults with inadequately-controlled chronic rhinosinusitis...
Regeneron continues New York expansion with $800M project, 1,500 jobs fiercepharma
September 14, 2018
Regeneron is supersizing a campus expansion in New York, investing $800 million and adding 1,500 jobs and winning a substantial tax break in the process.
Days after FDA rejection, Regeneron wins label expansion for Eylea fiercepharma
August 20, 2018
Regeneron started the week with a piece of bad news that the FDA rejected Eylea in a new 12-week dosing formulation. But in an extremely quick reversal by the regulator, Regeneron on Friday secured the approval.
Regeneron, Teva Announce Positive Fasinumab Results americanpharmaceuticalreview
August 17, 2018
Regeneron Pharmaceuticals and Teva Pharmaceutical announced positive topline results from a Phase 3, randomized, double-blind, placebo-controlled study of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip......
Regeneron, Teva’s pain drug clears phase 3 efficacy bar fiercebiotech
August 17, 2018
A phase 3 osteoarthritis trial of Teva and Regeneron’s fasinumab has met its co-primary endpoints. The anti-NGF antibody cleared the efficacy bar but triggered the expected safety alarms......
FDA stiff-arms Regeneron's bid for more convenient—and competitive—Eylea dosing fiercepharma
August 14, 2018
Regeneron, which was thinking its blockbuster eye drug Eylea would extend its market dominance with a new, more convenient 12-week dosing schedule for some patients, is having to think twice. The FDA has interrupted those plans with delivery of a CRL.
Regeneron, Bluebird ink anti-cancer cell therapy pact fiercebiotech
August 07, 2018
Regeneron and Bluebird bio have teamed up to develop anti-cancer cell therapies. The collaboration combines Regeneron’s antibody expertise with Bluebird’s cell therapy toolkit in a bid to expand the list of tumors modified T cells can treat.
Regeneron and Bluebird Bio collaborate on T-cells in $100 million deal pharmatimes
August 07, 2018
Regeneron and Bluebird Bio have announced that they will collaboration to apply their respective technology platforms to the discovery, development and commercialisation of novel immune cell therapies for cancer.
Regeneron plots DTC advertising and discount push to put Eylea back on track fiercepharma
August 03, 2018
Industry watchers already knew that Regeneron’s key new launches were hitting their marks, thanks to quarterly numbers Sanofi unveiled earlier this week. What they didn’t know was that top seller Eylea would fall short of expectations. But never fear, exe

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page